2017 American Transplant Congress
Porta Systemic Shunts Helps Us to Delay or Avoid Liver Transplantation in Patients with Portal Hypertension Post Kasai Operation for Biliary Atresia.
Paediatric Surgery and Transplant Surgery, Children's Hospital at Westmead, Sydney, NSW, Australia
We present a series of 10 patients who had Kasai operation for biliary atresia in the neonatal period. These patients had optimally functioning liver in…2017 American Transplant Congress
Disparities in Access to the Liver Transplant Wait List: A Statewide Analysis.
Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA
Background:Racial disparities in access to the liver transplant wait list for patients with end-stage liver disease (ESLD) are thought to be attributable to differences in…2017 American Transplant Congress
Are ICD-9 V Codes Representative of the Liver Transplant Wait List?
Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA
Background: Disparities in liver transplantation once wait listed are well-described, but little is known about how and why only 20% of end-stage liver disease patients…2016 American Transplant Congress
Transcatheter Aortic Valve Replacement (TAVR) for Severe Aortic Stenosis as a Bridge to Liver Transplantation.
Ochsner Medical Center, New Orleans, LA.
Background: Historically, severe symptomatic aortic stenosis (AS) has been corrected surgically with aortic valve replacement. In patients with end stage liver disease (ESLD), cardiac surgery…2016 American Transplant Congress
The Therapeutic Potential of Human Liver-Derived Stem Cell Transplantation in a Cirrhotic Liver Rat Model.
Cirrhosis is a long-term consequence of chronic hepatic injury and there are no effective treatment methods. Previous studies suggested that MSCs may ameliorate fibrogenesis through…2016 American Transplant Congress
Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?
Background: Combination antiviral therapy involving Sofosbuvir (SOF) & Simeprevir (SIM) +/- Ribavirin (RBV) is a relatively safe & effective Tx option in pts with gen…2016 American Transplant Congress
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.
Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…2016 American Transplant Congress
Impact of Left Ventricular Diastolic Dysfunction on Patients Being Evaluated for Liver Transplantation.
IntroductionDiastolic dysfunction (DD) is the cardinal finding in cirrhotic cardiomyopathy, a condition in patients with liver disease that is associated with an increased risk of…2016 American Transplant Congress
Liver Transplantation in Patients Actively Drinking Less Than 6 Months Before Transplant Presenting with Acute Decompensation: A Single-Center Experience.
Background: Alcohol is amongst the leading causes of liver disease worldwide. Most centers have a 6-month abstinence requirement before transplantation candidacy. Mortality rates for acute…
American Transplant Congress abstracts